Core Insights - Innovent Biologics has entered a strategic global collaboration with Takeda to advance next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) cancer therapies aimed at developing transformative cancer treatments for patients worldwide [1][2]. Collaboration Details - The partnership will focus on several investigational medicines within Innovent's IO+ADC pipeline, including IBI363, IBI343, and IBI3001, with IBI363 currently in Phase 3 clinical stage [2][4]. - Innovent and Takeda will co-develop IBI363 globally, sharing development costs at a ratio of 40/60, and will co-commercialize it in the U.S. [5][7]. - Takeda will receive exclusive commercialization rights for IBI343 outside Greater China, while also having an option for IBI3001 [5][10]. Financial Aspects - Innovent will receive an upfront payment of US$1.2 billion, which includes a strategic equity investment of US$100 million at a 20% premium to the average share price [13][14]. - The total deal value could reach up to US$11.4 billion, including potential milestone payments and royalties [14]. Product Highlights - IBI363 is a first-in-class PD-1/IL-2 bispecific antibody fusion protein that has shown promising results in clinical trials, particularly in immunotherapy-resistant lung cancer [4][6]. - IBI343 is an innovative ADC targeting CLDN18.2, currently in Phase 3 trials for gastric and gastroesophageal cancers, and has received Breakthrough Designation in China [9][10]. - IBI3001 is a first-in-class bispecific ADC targeting B7-H3 and EGFR, currently in Phase 1 clinical trials [11][12]. Strategic Goals - The collaboration aims to redefine cancer treatment globally by leveraging Innovent's R&D capabilities and Takeda's extensive experience in drug development and commercialization [3][5]. - This partnership is a significant step in Innovent's strategic roadmap to expand its global footprint and enhance its position as a leading biopharmaceutical company [3].

Core Viewpoint - Xinda Biopharmaceutical has entered into a global strategic collaboration with Takeda Pharmaceutical to accelerate the development of its next-generation IO and ADC therapies, with a total deal value potentially reaching $11.4 billion [1] Group 1: Collaboration Details - The collaboration includes two late-stage therapies, IBI363 and IBI343, and an early-stage project, IBI3001 [1] - Xinda Biopharmaceutical and Takeda will jointly develop IBI363 globally, with Takeda leading the development efforts in the U.S. [1] - Xinda grants Takeda commercialization rights for IBI363 outside of Greater China and the U.S., while Takeda receives exclusive rights for IBI343 outside of Greater China [1] Group 2: Financial Aspects - Xinda will receive an upfront payment of $1.2 billion, which includes a strategic equity investment of $100 million [1] - The company is eligible for up to $10.2 billion in potential milestone payments, making the total deal value potentially reach $11.4 billion [1] - Xinda will also receive a share of potential sales for each candidate drug outside of Greater China, with a profit-sharing model for IBI363 in the U.S. [1]

Core Insights - The company has entered into a global strategic collaboration with Takeda Pharmaceuticals to accelerate the development of its next-generation IO and ADC therapies, aiming to expand its global market value [1][3] Group 1: Collaboration Details - The collaboration includes two late-stage therapies, IBI363 (PD-1/IL-2α-bias) and IBI343 (CLDN18.2 ADC), as well as an early-stage project, IBI3001 (EGFR/B7H3 ADC) [1] - The company will jointly develop IBI363 with Takeda and will commercialize it in the U.S., while Takeda will lead the development under a collaborative governance structure [1][3] - Takeda has been granted exclusive rights for IBI343 outside Greater China, and an exclusive option for IBI3001 outside Greater China [1] Group 2: Financial Aspects - The company will receive an upfront payment of $1.2 billion, including a strategic equity investment of $100 million at a 20% premium to the weighted average closing price of the shares over the 30 trading days prior to the agreement [2][4] - The total potential milestone payments could reach up to $10.2 billion, making the total transaction value up to $11.4 billion [2] - The net proceeds from the share issuance will be allocated 80% to R&D for various clinical and preclinical projects and 20% for general corporate purposes [3] Group 3: Strategic Importance - The collaboration is viewed as a significant step towards the company's long-term development and aligns with its mission to become a leading global biopharmaceutical enterprise [3] - The partnership combines the company's expertise in IO and ADC fields with Takeda's extensive experience in global oncology drug development and commercialization [3] - This collaboration is expected to enhance the company's global footprint and establish capabilities in R&D and commercialization in key international markets, maximizing sustainable long-term value [3]

Core Insights - Company enters a global strategic partnership with Takeda Pharmaceuticals to accelerate the development of next-generation IO and ADC therapies, expanding global market value [1] - The collaboration includes late-stage therapies IBI363 (PD-1/IL-2) and IBI343 (CLDN18.2ADC), as well as an early-stage project IBI3001 (EGFR/B7H3 ADC) [1] Group 1 - The partnership allows for joint development of IBI363 (PD-1/IL-2) globally, with Takeda leading the commercialization efforts in the U.S. [1] - Company grants Takeda commercialization rights for IBI363 outside Greater China and the U.S. [1] - Takeda receives exclusive rights for IBI343 (CLDN18.2ADC) outside Greater China and an exclusive option for IBI3001 (EGFR/B7H3 ADC) outside Greater China [1] Group 2 - Company will receive an upfront payment of $1.2 billion, including a strategic equity investment of $100 million at a 20% premium to the weighted average closing price over the previous 30 trading days [2] - Potential milestone payments could total up to $10.2 billion, making the total transaction value up to $11.4 billion [2] - Company will also receive a share of potential sales for each candidate drug outside Greater China, with a profit-sharing model for IBI363 in the U.S. [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告僅供參考之用，並不構成收購、購買或認購本公司任何證券之邀請或要約。 信達生物制藥 本公告由本公司根據香港聯合交易所有限公司證券上市規則第13.09條及第13.28 條以及香港法例第571章證券及期貨條例第XIVA部作出。 與武田製藥達成全球戰略合作，加速本公司新一代IO及ADC療法推向全 球市場 董事會欣然宣佈，於2025年10月22日（香港時間），信達生物與武田製藥（透過 武田製藥全資附屬公司Takeda Pharmaceuticals International AG）達成全球戰略 合作，旨在加速推進信達生物新一代IO及ADC療法開發，拓展全球市場價值。 本次合作包括兩款後期在研療法IBI363 (PD-1/IL-2α-bias)及IBI343 (CLDN18.2 ADC)，以及一款早期研發項目IBI3001 (EGFR/B7H3 ADC)的選擇權。 根據合作，信達生物與武田製藥將在全球範圍內 ...

Core Insights - On October 21, Shandong Molong made its first appearance on the Hong Kong Stock Connect active trading list in the past month, with a trading volume of 1.147 billion HKD and a net buying amount of 48 million HKD, closing up 8.39% [1] Trading Activity Summary - The total trading volume of active stocks on the Hong Kong Stock Connect reached 44.268 billion HKD, accounting for 35.00% of the day's total trading amount, with a net buying amount of 868 million HKD [1] - Alibaba-W led the trading volume with 10.33 billion HKD, followed by SMIC and Pop Mart with trading amounts of 7.805 billion HKD and 5.897 billion HKD, respectively [1] Stock Performance Overview - The most frequently listed stocks in the past month include Alibaba-W and Huahong Semiconductor, each appearing 16 times, indicating strong interest from Hong Kong Stock Connect investors [1] - Shandong Molong's trading activity on October 21 marked its first listing in the past month, with a notable increase in its stock price [1]

Market Overview - On October 21, the Hang Seng Index rose by 0.65%, with total southbound trading amounting to HKD 126.49 billion, including buy transactions of HKD 63.83 billion and sell transactions of HKD 62.66 billion, resulting in a net buying amount of HKD 1.17 billion [1] Southbound Trading Details - The southbound trading through Stock Connect (Shenzhen) had a cumulative trading amount of HKD 45.84 billion, with buy transactions of HKD 22.25 billion and sell transactions of HKD 23.60 billion, leading to a net selling amount of HKD 1.35 billion [1] - Conversely, the Stock Connect (Shanghai) recorded a cumulative trading amount of HKD 80.65 billion, with buy transactions of HKD 41.59 billion and sell transactions of HKD 39.06 billion, resulting in a net buying amount of HKD 2.52 billion [1] Active Stocks - Among the actively traded stocks, Alibaba-W had the highest trading amount at HKD 103.30 billion, followed by SMIC with HKD 78.05 billion and Pop Mart with HKD 58.97 billion [1] - In terms of net buying, Pop Mart led with a net buying amount of HKD 11.21 billion despite a closing price drop of 8.08%, followed by Xiaomi Group-W with HKD 4.81 billion and Hua Hong Semiconductor with HKD 4.41 billion [1] - The stock with the highest net selling was the Tracker Fund of Hong Kong, with a net selling amount of HKD 11.02 billion, while Alibaba-W and Innovent Biologics experienced net selling amounts of HKD 4.30 billion and HKD 0.78 billion, respectively [1] Detailed Stock Performance - The following table summarizes the trading performance of selected stocks on October 21: - Pop Mart: Total trading amount of HKD 589.69 million, net buying of HKD 112.07 million, with a price drop of 8.08% [3] - Xiaomi Group-W: Total trading amount of HKD 357.59 million, net buying of HKD 48.11 million, with a price drop of 1.44% [3] - Hua Hong Semiconductor: Total trading amount of HKD 366.72 million, net buying of HKD 44.13 million, with a price drop of 0.26% [3] - Tencent Holdings: Total trading amount of HKD 461.03 million, net selling of HKD 3.19 million, with a price increase of 0.48% [3] - Alibaba-W: Total trading amount of HKD 1,033.04 million, net selling of HKD 42.98 million, with a price increase of 1.98% [3] - Tracker Fund of Hong Kong: Total trading amount of HKD 111.86 million, net selling of HKD 110.23 million, with a price increase of 0.68% [3]

Core Points - The Hang Seng Index rose by 0.65% to close at 26,027.55 points on October 21, with a net inflow of HKD 1.171 billion from southbound funds through the Stock Connect [1] - The total trading volume for the Stock Connect on the same day was HKD 126.489 billion, with a net buy of HKD 1.171 billion [1] - In the Shanghai Stock Connect, the trading volume was HKD 80.647 billion with a net buy of HKD 2.524 billion, while the Shenzhen Stock Connect had a trading volume of HKD 45.843 billion with a net sell of HKD 1.353 billion [1] Trading Activity - The most actively traded stock in the Shanghai Stock Connect was Alibaba-W, with a trading volume of HKD 6.587 billion, followed by SMIC and Pop Mart, with trading volumes of HKD 4.678 billion and HKD 4.097 billion, respectively [1] - In terms of net buying, Pop Mart led with a net inflow of HKD 0.683 billion, despite its stock price dropping by 8.08% [1] - Alibaba-W had the highest net sell amount of HKD 0.133 billion, while its stock price increased by 1.98% [1] Shenzhen Stock Connect Activity - In the Shenzhen Stock Connect, Alibaba-W also topped the trading volume with HKD 3.743 billion, followed by SMIC and Pop Mart with HKD 3.127 billion and HKD 1.800 billion, respectively [2] - Pop Mart again had the highest net buy amount of HKD 0.438 billion, despite a closing price drop of 8.08% [2] - The stock with the largest net sell was the Tracker Fund of Hong Kong, with a net sell of HKD 1.102 billion, while its stock price rose by 0.68% [2]

Group 1 - On October 21, 2025, Alibaba-W (09988), SMIC (00981), and Pop Mart (09992) ranked as the top three companies by trading volume in the Southbound Stock Connect, with transaction amounts of 6.587 billion, 4.678 billion, and 4.097 billion respectively [1] - In the Southbound Stock Connect for the Shenzhen-Hong Kong Stock Connect, Alibaba-W (09988), SMIC (00981), and Pop Mart (09992) also held the top three positions, with transaction amounts of 3.743 billion, 3.127 billion, and 1.800 billion respectively [1] Group 2 - In the Southbound Stock Connect, the top active trading companies included Alibaba-W (09988) with a transaction amount of 6.587 billion and a net buy of -0.133 billion, SMIC (00981) with 4.678 billion and a net buy of -51.9952 million, and Pop Mart (09992) with 4.097 billion and a net buy of +683 million [2] - For the Shenzhen-Hong Kong Stock Connect, the top active trading companies were Alibaba-W (09988) with a transaction amount of 3.743 billion and a net buy of -0.296 billion, SMIC (00981) with 3.127 billion and a net buy of +180 million, and Pop Mart (09992) with 1.800 billion and a net buy of +438 million [2]

Market Overview - The Hong Kong stock market continues its upward trend, with the Hang Seng Index rising by 0.65%, the Hang Seng Tech Index increasing by 1.26%, and the Hang Seng China Enterprises Index up by 0.76%, indicating a broad market rally with 1,315 stocks rising and 883 falling [1] - Southbound funds recorded a net purchase of HKD 1.171 billion on a single day, signaling renewed buying interest after a brief outflow [4] Stock Performance - The most favored stocks included Pop Mart, Xiaomi Group-W, and Hua Hong Semiconductor, which saw net purchases of HKD 1.121 billion, HKD 0.481 billion, and HKD 0.441 billion, respectively [4] - Conversely, the iShares Asia 50 ETF, Alibaba-W, and Innovent Biologics experienced varying degrees of net selling, with net sales of HKD 1.102 billion, HKD 4.3 billion, and HKD 0.78 billion, respectively [5] Future Outlook - According to Guotai Junan, historical data suggests that minor pullbacks in the Hong Kong market often occur after profit-taking following market rallies, with the Hang Seng Index typically declining by an average of 7% over 11 trading days [6] - The report emphasizes that short-term fluctuations do not alter the medium-term positive trend, with the technology sector remaining the main investment focus amid an upward industrial cycle and increased capital inflow [6] - Guoyuan International highlights that the primary external uncertainty remains the US-China rivalry, which could impact investor sentiment and lead to short-term market volatility, but there is a significant likelihood that the Hang Seng Index will return to an upward trajectory [6]